Endexx Corporation (OTC: EDXC), a provider of medical marijuana management and technology solutions, recently announced that its Cannsumable division would be providing its CBD Starter Kit M3Vape to a voluntary patient study that seeks to determine the effects of industrial hemp oil that is rich in CBD/CBDa on patients suffering from diabetic neuropathy.
While the study is not a formal clinical trial, Dr. Daniel Kiddy began observing 13 diabetic patients suffering from neuropathy in Missouri for a 30-day period. The study’s objective is to see if pain is decreased or eliminated, as well as monitor the proprioception and sharp and dull sensations for improvement. Dr. Kiddy is hoping that the study will provide anecdotal feedback from patients to doctors.
Endexx has traditionally provided seed-to-sale compliance, security, tracking, and dispensing via its Autospense and m3hub technology platforms. Since then, management has diversified into the CBD consumable segment and established a complete supply chain for CBD oil that it has sourced and tested and is now selling and distributing throughout the United States to patients in need.
Over the coming weeks, the company will deploy its Autospense technology at the Pure Medical Marijuana Dispensary located in Denver, Colorado. The 100-day pilot program is designed to test for compliance and tracking integration under the rules established by the Marijuana Enforcement Division of Colorado, while testing the company’s technology in a live environment before fully launching it.
Endexx management is also working diligently to become fully reporting and up-list to the OTCQB over the coming quarters. By doing so, the company could unlock significant value for shareholders by increasing transparency and embracing best practices. The up-listing could also open the door to additional investment from institutions that require such disclosures before committing capital.
Shares of Endexx Corporation were trading even in early trading on Tuesday, December 9, 2014 following the news release.
Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.